Kexing Biopharm Co., Ltd. Class A 688136
SSE · Çin · Sağlık Teknolojisi
CNY 24,27+0,70 (+%2,97)
Piyasa kapalı· · CNY · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Piyasa kapalı· · CNY · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
San Diego, California--(Newsfile Corp. - June 29, 2026) - Recently, the Head of Global Business Development at Kexing Biopharm Co., Ltd. (hereinafter referred to as "Kexing Biopharm", 688136.SH) was invited to attend the 2026 BFC-Cytiva Global Healthcare Summer BD & Investment Conference. She delivered a roadshow speech showcasing the Company's innovative pipeline in autoimmune diseases, oncology, and ophthalmology to the global pharmaceutical and investment communities, highlighting the latest.
From June 16 to 18, the CPHI & PMEC China 2026 was held at the Shanghai New International Expo Center. Kexing Biopharm (688136.SH) showcased multiple self-developed innovative drug pipelines and over 30 products for international markets at the exhibition. The company was also invited to attend the CPHI Award ceremony and received the R&D Innovation Award for its achievements in innovation and international development.
Earlier this week, IQVIA Holdings announced an expanded collaboration with Kexing Biopharm to support a global, multi-product biosimilar development and commercialization program using its AI-enabled clinical trial capabilities across design, site selection and execution. This partnership highlights how IQVIA is using integrated data, analytics and clinical expertise to help biopharma clients execute complex international biosimilar strategies under a single coordinated framework. Next,...
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.